Скачать или смотреть What are the advantages of co-targeting of LAG-3 and PD-1 in oncology?

Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Hospital Universitario Quirónsalud Madrid, Madrid, Spain, comments on the benefits of a bispecific antibody targeting LAG-3 and PD-1 over individual targeting. There is potential for more efficient modulation of the immune synapse, more predictable pharmacokinetics and pharmacodynamics, and easier dosing, which could lead to higher efficacy with less toxicity. These targets are well-known and validated, particularly in melanoma, and that co-targeting them at the single cell level could have several benefits. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.